Arbutus to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in two upcoming investor conferences in New York:

1. H.C. Wainwright 26th Annual Global Investment Conference: Formal presentation on September 9, 2024, at 8:00 am ET

2. Baird Global Healthcare Conference: Fireside chat on September 10, 2024, at 8:30 am ET

The Arbutus management team will participate in and host one-on-one meetings at both events. Interested parties can access live webcasts of the presentation and fireside chat through the company's investor relations website. Archived replays will be available for a time after the events.

WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:

• H.C. Wainwright 26^th Annual Global Investment Conference: Formal Presentation on September 9, 2024 at 8:00 am ET
• Baird Global Healthcare Conference: Fireside Chat on September 10, 2024 at 8:30 am ET

To access the live webcast of the presentation and fireside chat please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

FAQ

When is Arbutus Biopharma (ABUS) presenting at the H.C. Wainwright Global Investment Conference?

Arbutus Biopharma (ABUS) is scheduled to give a formal presentation at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 8:00 am ET.

What type of event is Arbutus Biopharma (ABUS) participating in at the Baird Global Healthcare Conference?

Arbutus Biopharma (ABUS) will participate in a fireside chat at the Baird Global Healthcare Conference on September 10, 2024, at 8:30 am ET.

Where can investors access the webcasts of Arbutus Biopharma's (ABUS) conference presentations?

Investors can access the live webcasts of Arbutus Biopharma's (ABUS) conference presentations at https://investor.arbutusbio.com/events-presentations.

What is the main focus of Arbutus Biopharma's (ABUS) research and development?

Arbutus Biopharma (ABUS) is focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, leveraging its extensive virology expertise.